English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 22 September 2020, 07:50 HKT/SGT
Share:
    

Source: Avance Clinical
Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America

ADELAIDE, AUS, Sept 22, 2020 - (ACN Newswire) - The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis. www.avancecro.com/eclinical-solutions

Avance Clinical made the announcement at BioPharm America (September 21-24, 2020)

Avance Clinical's biotech clients now have the option to deploy the latest eClinical solutions to maximise the value of study data and deliver real-time visibility on study progress.

Avance Clinical CEO Yvonne Lungershausen said:
"Our Data Management team works with eClinical leaders such as Medrio to offer regulatory compliant and patient centric tools for rapid start-up and continual data flow. These tools improve patient engagement and data collection and allow Sponsors to stay informed at every step with Sponsor visible portals."

The Avance Clinical eClinical services include the following:

eSource
- Direct data capture of source data on site
- Forms customised by Avance Clinical Data Management team
- Edit checks built into forms; instant firing of queries once data is entered
- Option for data to be collected off-line and synced when on-line is available
- Fully integrated with Medrio EDC, data visible for Sponsor review instantly
- Remote monitoring and data review on ongoing basis
- Avance Clinical provision of tablets if required

eConsent
- Electronic consent including patient sign-off and investigator confirmation
- Customisable to include animations, videos and questions as required
- Forms customised by Avance Clinical Data Management team
- Link via email to patient
- Compatible with any device and internet system (smart phones, tablet, laptop, desktop)
- Integrated with Medrio EDC
- Link can be shared with HREC as part of submission package

ePRO
- Electronic capture of patient reported outcome, including diary data, dosing compliance, questionnaires, VAS/Pain scales
- Forms customised by Avance Clinical Data Management team
- Link via email to patient
- Options for emails and reminders at set times during the day or week
- Timezone adjusted to patient's location
- Compatible with any device and internet system (smart phones, tablet, laptop, desktop)
- Fully integrated with Medrio EDC, data visible for Sponsor review instantly

Glynn Morrish, Avance Clinical Director Biometrics said:
"Direct electronic capture of study information and the complimentary suite of solutions offered by Avance Clinical allows the company and its clients to maximise clinical trial efficiency and flexibility while ensuring data integrity is preserved. Our highly trained and experienced biometrics team are excited to continue to work at the forefront of innovation and technology and provide services that offer stability and robustness to studies being conducted in an ever-changing global environment."

Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.

Considering Australia? Contact us about your next study. https://www.avancecro.com/eclinical-solutions/

About Avance Clinical www.avancecro.com

Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. eClinical solutions - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons

Media Contact:
media@avancecro.com
Chris Thompson

Topic: Press release summary
Source: Avance Clinical

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Avance Clinical Related News
June 4, 2024 22:56 HKT/SGT
BIO24에서 발표된 새로운 연구에서 내부 규제 사항을 갖춘 CRO는 생명공학 기업에게 30%의 절감을 제공하고, 시간을 절반으로 줄이며, 위험을 줄입니다
June 4, 2024 22:46 HKT/SGT
新研究發現,具有內部監管事務的CRO公司為生物技術公司節省30%的成本,縮短時間線一半,降低風險
June 4, 2024 22:25 HKT/SGT
新研究发现,具有内部监管事务的CRO公司为生物技术公司节省30%的成本,缩短时间线一半,降低风险
June 4, 2024 22:00 HKT/SGT
New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs
June 1, 2024 06:00 HKT/SGT
Avance Clinical透過與Julius Clinical合作,在歐洲擴展專門的中樞神經系統、心血管代謝和罕見疾病的CRO服務
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575